Charles Schwab Investment Management Inc. Acquires 42,233 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Charles Schwab Investment Management Inc. boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,125,535 shares of the company’s stock after buying an additional 42,233 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.24% of Myriad Genetics worth $15,431,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. State Street Corp increased its position in Myriad Genetics by 8.3% in the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock worth $128,827,000 after buying an additional 359,685 shares during the period. Disciplined Growth Investors Inc. MN increased its position in Myriad Genetics by 21.1% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock worth $69,226,000 after buying an additional 440,107 shares during the period. Loomis Sayles & Co. L P increased its position in Myriad Genetics by 153.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock worth $59,973,000 after buying an additional 1,326,497 shares during the period. Geode Capital Management LLC grew its holdings in shares of Myriad Genetics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,154,035 shares of the company’s stock worth $59,010,000 after purchasing an additional 21,220 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Myriad Genetics by 26.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company’s stock worth $29,135,000 after purchasing an additional 224,255 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Price Performance

Myriad Genetics stock opened at $9.91 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a market cap of $904.87 million, a P/E ratio of -7.62 and a beta of 1.79. The business’s fifty day moving average is $12.23 and its two-hundred day moving average is $17.30. Myriad Genetics, Inc. has a 52 week low of $9.36 and a 52 week high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The business had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the prior year, the firm posted ($0.12) EPS. Equities research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on MYGN shares. Craig Hallum started coverage on Myriad Genetics in a report on Wednesday, February 12th. They set a “buy” rating and a $29.00 price objective on the stock. Bank of America decreased their price objective on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a report on Monday, March 3rd. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday, March 13th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Finally, UBS Group decreased their price objective on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, February 25th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $21.89.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.